Abstract
AbstractThe ability of Mycobacterium tuberculosis (Mtb) to adopt heterogeneous physiological states underlies its success in evading the immune system and tolerating antibiotic killing. Drug tolerant phenotypes are a major reason why the tuberculosis (TB) mortality rate is so high, with over 1.8 million deaths annually. To develop new TB therapeutics that better treat the infection (faster and more completely), a systems-level approach is needed to reveal the complexity of network-based adaptations of Mtb. Here, we report a new predictive model called PRIME (Phenotype of Regulatory influences Integrated with Metabolism and Environment) to uncover environment-specific vulnerabilities within the regulatory and metabolic networks of Mtb. Through extensive performance evaluations using genome-wide fitness screens, we demonstrate that PRIME makes mechanistically accurate predictions of context-specific vulnerabilities within the integrated regulatory and metabolic networks of Mtb, accurately rank-ordering targets for potentiating treatment with frontline drugs.
Funder
U.S. Department of Health & Human Services | National Institutes of Health
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Subject
Applied Mathematics,Computer Science Applications,Drug Discovery,General Biochemistry, Genetics and Molecular Biology,Modelling and Simulation
Reference45 articles.
1. Stanley, S. A. & Cox, J. S. Host–pathogen interactions during Mycobacterium tuberculosis infections. Curr. Top. Microbiol. Immunol. 410, 211–241 (2013).
2. Rienksma, R. A., Schaap, P. J., Martins dos Santos, V. A. P. & Suarez-Diez, M. Modeling the metabolic state of Mycobacterium tuberculosis upon infection. Front. Cell. Infect. Microbiol. 8, 1–13 (2018).
3. Galagan, J. E. et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 499, 178–183 (2013).
4. Chaulk, C. P. & Kazandjian, V. A. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus statement of the public health tuberculosis guidelines panel. J. Am. Med. Assoc. 279, 943–948 (1998).
5. Sarathy, J. P. et al. Extreme drug tolerance of Mycobacterium tuberculosis in Caseum. Antimicrob. Agents Chemother. 62, e02266–17 (2018).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献